Disease burden of schizophrenia patients visiting a Chinese regional mental health centre
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim & methods: A decision-analytic model was constructed to simulate a real-world cohort of Chinese patients visiting a Chinese regional mental health center for long-term health outcomes and direct medical costs. Results: When compared with age and gender-matched general population, the Chinese patients with schizophrenia were associated with reduced overall survival by 20.6 years (27.6 vs 48.2 years) and reduced quality-adjusted life years (QALY) by 18.4 QALY (18.4 vs 36.8 QALY), respectively, and increased lifetime direct medical costs by about three-times (US$84,324 vs 33,387 as of 31 December 2017) on average. Conclusion: The burden of schizophrenia was mainly driven by the mortality associated with relapsed schizophrenia and direct medical costs for schizophrenia in local mental health rehabilitation institutes.
Formats available
You can view the full content in the following formats:
References
1.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Edition). American Psychiatric Association, Washington DC, USA (2013).
2.
Whiteford HA, Degenhardt L, Rehm J et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382(9904), 1575–1586 (2013).
3.
National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: prevention and management. National Clinical Practice Guidelines number CG178 (2014). www.nice.org.uk/guidance/cg178
4.
Chan KY, Zhao FF, Meng S et al. Prevalence of schizophrenia in China between 1990 and 2010. J. Glob. Health 5(1), 010410 (2015).
5.
Xu J, Wang J, Wimo A, Qiu C. The economic burden of mental disorders in China, 2005–2013: implications for health policy. BMC Psych. 16(1), 137 (2016).
6.
Brown S. Excess mortality of schizophrenia: a meta-analysis. Brit. J. Psych. 171(6), 502–508 (1997).
7.
Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr. Bull. 33(5), 1225–1237 (2007).
8.
Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr. Bull. 30(2), 279–293 (2004).
9.
Andrews G, Henderson S. (Eds). Unmet Need in Psychiatry: Problems, Resources, Responses. Cambridge University Press, UK (2000).
10.
Yan F, Yang Y, Huang Q et al. Cost–effectiveness of a free drug program for schizophrenia in Beijing, China. Int. J. Social Psych. 65(1), 28–37 (2019).
11.
Muirhead D, Harvey C, Ingram G. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aus. NZ J. Psych. 40(6–7), 596–605 (2006).
12.
Liu J, Ma H, He YL et al. Mental health system in China: history, recent service reform and future challenges. World Psych. 10(3), 210–216 (2011).
13.
Lieberman JA, Stroup TS, Mcevoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
14.
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 127(1–3), 83–92 (2011).
15.
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J. Clin. Psych. 67(3), 453–460 (2006).
16.
Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Brit. J. Psych. 195(Suppl. 52), S63–S67 (2009).
17.
Liu J, Ma H, He YL et al. Mental health system in China: history, recent service reform and future challenges. World Psych. 10(3), 210–216 (2011).
18.
China Banking and Insurance Regulatory Commission. China life insurance lifetable (2016). www.cbirc.gov.cn/cn/view/pages/ItemDetail.html?docId=372677&itemId=925&generaltype=0
19.
Sun S, Chen J, Johannesson M et al. Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual. Life Res. 20(3), 309–320 (2011).
20.
National Health Commission of P.R. China. 2017 China health care development annual report (2018). www.nhc.gov.cn/guihuaxxs/s10743/201806/44e3cdfe11fa4c7f928c879d435b6a18.shtml
21.
Hunan Provincial Bureau of Statistics. Main data bulletin of the national sampling survey of 1% population in Hunan province in 2015 (2016). http://tjj.hunan.gov.cn/tjfx/tjgb/rkpc/201605/t20160524_3800859.html
22.
Siani C, De Peretti C, Millier A, Boyer L, Toumi M. Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC. Qual. Life Res. 25(4), 925–934 (2016).
23.
Xiang Y-T, Wang C-Y, Weng Y-Z et al. Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study. Soc. Psych. Psychiatr. Epidemiol. 46(12), 1325–1330 (2011).
24.
Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. North Am. 30(3), 437–452 (2007).
25.
Hjorthøj C, Stürup AE, Mcgrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psych. 4(4), 295–301 (2017).
26.
Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690), 620–627 (2009).
27.
Ma X, Xiang Y-T, Cai Z-J et al. Lifetime prevalence of suicidal ideation, suicide plans and attempts in rural and urban regions of Beijing, China. Aust. NZ J. Psych. 43(2), 158–166 (2009).
28.
Ran M. A study of schizophrenic patients' treatment compliance in a rural community. J. Ment. Health 4(1), 85–90 (1995).
29.
Xiang Y-T, Yu X, Sartorius N, Ungvari GS, Chiu HF. Mental health in China: challenges and progress. Lancet 380(9855), 1715–1716 (2012).
Information & Authors
Information
Published In
Pages: 469 - 481
PubMed: 32301625
Copyright
© 2020 Future Medicine Ltd.
History
Received: 22 August 2019
Accepted: 24 February 2020
Published online: 17 April 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Disease burden of schizophrenia patients visiting a Chinese regional mental health centre. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0129
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Yan Gu, Yong He, Yingying Xie, Wenqian Lu, Hao Liu, Yan Li, Gangqin Li, Distinctive and common risk factors contributing to violent offending in patients with schizophrenia compared to people without a mental illness, International Journal of Law and Psychiatry, 10.1016/j.ijlp.2026.102192, 105, (102192), (2026).
- Hong Ma, Jun Cai, Fujun Jia, Jiansong Zhou, Bo Zhou, Wanyi Zhang, Chong Ye, Miaomiao Jia, Tianmei Si, Clinical Practice Recommendations for Switching from Once-Monthly to Longer-Interval Paliperidone Palmitate Injectable in Schizophrenia Patients: A Modified Delphi Study in China, Neuropsychiatric Disease and Treatment, 10.2147/NDT.S579943, Volume 22, (1-14), (2026).
- Hua Ren, Qin Yang, Changjiu He, Jian Jiao, Zaiquan Dong, Community management: An effective model to reduce medication discontinuation rate in patients with schizophrenia, PLOS One, 10.1371/journal.pone.0324114, 21, 1, (e0324114), (2026).
- Sihan Zhao, Yonghou Zhao, Ming Yu, Jianbo Chai, Xinhui Yao, A Systematic Review of Traditional Uses, Phytochemistry, and Pharmacology of Chinese Herb Medicine for Schizophrenia, Journal of Clinical Pharmacy and Therapeutics, 10.1155/jcpt/9996801, 2025, 1, (2025).
- Xiao Liu, Xiao-yu Wang, Bing-zhe Chen, Yu-mei Su, Run-hui Pang, Risk prediction model development for requiring unplanned psychiatric readmission in bipolar disorder, Scientific Reports, 10.1038/s41598-025-17142-7, 15, 1, (2025).
- Yuting Tan, Guiling Chen, Shuge Wang, Xingxin Zhan, Rong Cheng, Linru Qiao, Zhixia Zhang, Yaping Liu, Machine Learning and Interpretability Study for Predicting 30-Day Unplanned Readmission Risk of Schizophrenia: A Retrospective Study, Neuropsychiatric Disease and Treatment, 10.2147/NDT.S522675, Volume 21, (1509-1521), (2025).
- Hong Cai, Pan Chen, Qinge Zhang, Mei Ieng Lam, Tong Leong Si, Yu-Fei Liu, Wan-Ying Zheng, Zhaohui Su, Teris Cheung, Todd Jackson, Gabor S. Ungvari, Zhihong Ren, Xinyue Li, Xiao-Hong Li, Yu-Tao Xiang, Global prevalence of major depressive disorder in LGBTQ+ samples: A systematic review and meta-analysis of epidemiological studies, Journal of Affective Disorders, 10.1016/j.jad.2024.05.115, 360, (249-258), (2024).
- Mingru Hou, Yuqing Wu, Jianhua Xue, Qiongni Chen, Yan Zhang, Ruifen Zhang, Libo Yu, Jun Wang, Zhenhe Zhou, Xianwen Li, A predictive model for readmission within 1-year post-discharge in patients with schizophrenia, BMC Psychiatry, 10.1186/s12888-024-06024-3, 24, 1, (2024).
- Yujing Sun, Hong Yu, Zhengjun Wang, Jing Zhang, Yuqiu Zhou, Wenming Cui, Wenlong Jiang, Relationship between medication burden and medication experience in stable patients with schizophrenia: the mediating effect of medication belief, BMC Nursing, 10.1186/s12912-024-01882-4, 23, 1, (2024).
- Xu Yang, Haidong Yang, Na Li, Chunyu Li, Weiye Liang, Xiaobin Zhang, Increased serum homocysteine in first episode and drug-naïve individuals with schizophrenia: sex differences and correlations with clinical symptoms, BMC Psychiatry, 10.1186/s12888-022-04416-x, 22, 1, (2022).